These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24509751)

  • 1. Biologic product identification and US pharmacovigilance in the biosimilars era.
    Felix T; Johansson TT; Colliatie JA; Goldberg MR; Fox AR
    Nat Biotechnol; 2014 Feb; 32(2):128-30. PubMed ID: 24509751
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of the United States' naming convention for biological products.
    Saunders J; Proctor C; Shermock KM
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):750-753. PubMed ID: 32319139
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
    Sugay J
    Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
    Wright EE; Blevins TC; Reed B; Pollom RD
    J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
    Stergiopoulos S; Getz K
    Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Draft Guidance on the Naming of Biosimilars.
    Fernandez-Lopez S
    BioDrugs; 2015 Oct; 29(5):323-5. PubMed ID: 26481940
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance Considerations for Biosimilars in the USA.
    Grampp G; Felix T
    BioDrugs; 2015 Oct; 29(5):309-21. PubMed ID: 26419971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
    Jordan JB; Christl L
    Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competition in the Age of Biosimilars.
    Chandra A; Vanderpuye-Orgle J
    JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
    Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
    Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.